Myasthenia Gravis Pipeline Insight and Ongoing Therapeutic Assessment Covering Drug Profiles in 2017

Published on : Aug 21, 2017

Albany, New York, August 21, 2017: According to a study, autoimmune diseases come in many different forms, affecting millions of people. Myasthenia Gravis is such an autoimmune disease resulting from some abnormality which leads to incorrect flow of chemicals in the nervous system. There are several researches are being done by pharmaceutical companies to provide better treatment for the patients fighting with the disease. To elaborate further, a pipeline study titled “Myasthenia Gravis-Pipeline Insight, 2017” has been broadcasted to the wide repository of Market Research Hub (MRH). This research study aims to provide comprehensive insights of the ongoing therapeutic research and development across Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action, route of administration (RoA) and molecule type.

In the first part of the study, the report presents brief overview of Myasthenia gravis along with its pipeline therapeutics and pipeline products involved in this assessment. Myasthenia gravis is characterized by weakness and rapid fatigue of the voluntary muscles. This condition is more common in women younger than 40 and in men older than 60. It most commonly affects the muscles that control the eyes and eyelids, facial expressions, speaking, chewing and swallowing. It has been analyzed that MG is an autoimmune disease with no known cause or cure. However, treatments are available which stabilize the myasthenics' condition or sometimes lead to long-term remission. Myasthenia gravis (MG), once a uniformly disabling can be managed effectively with present therapeutic strategies.

Furthermore, the report provides pipeline product profiles which contain product description, developmental activities, licensors & collaborators and chemical information. Also, report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Myasthenia Gravis.

Even though no severely tested treatment trials have been reported and no clear consensus occurs on treatment strategies, myasthenia gravis (MG) is one of the most treatable neurologic disorders. Study finds that Myasthenia gravis (MG) can be treated with drugs, surgery and other therapies, alone or in combination. Through this pipeline analysis, the report aims to establish the understanding for all the pipeline drugs that are undergoing research across Myasthenia Gravis. Commonly used immunotherapeutic drugs in MG are prednisone, cyclosporine, azathioprine and mycophenolate mofetil.

Moreover, the report contains details on dormant products and discontinued products of the active players involved in therapeutic market of Myasthenia Gravis. This pipeline study is built using data and information sourced from registered databases, primary and secondary research and in-house analysis by the team of industry experts.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top